The FDA granted conditional approval for Eli Lilly's Jaypirca for treating adult patients with chronic lymphocytic leukemia or small lymphocytic lymphoma who have undergone at least two prior therapies. The approval, under the FDA's Accelerated Approval pathway, was based on the Phase 1/2 BRUIN trial results, which showed a 72% overall response rate. Jaypirca is the first FDA-approved non-covalent BTK inhibitor and comes with specific warnings and precautions. This follows a previous approval in January 2023 for a different indication.